No profile data available.
Sareum Holdings plc (SAR.L) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Cambridge, United Kingdom, with about 5 full-time employees.
Its market capitalization was 38.42 million GBP as of October 7, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2024; market data as of October 7, 2026.
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases.
38.42 million GBP as of October 7, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include ImmuPharma plc (IMM.L).